PLOS ONE: Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Trial Finds Advantage in Overall Response Rate for subtypes of MDS Patients Receiving Azacitidine Combination Therapy – Consult QD
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
ORR (Objective Response Rate) and related statistics – Part 1
Sirtex - Response Rate
Table 2 from Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy | Semantic Scholar
Efficacy | BALVERSA® (erdafitinib) HCP
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Durable Response Rate
RESONATE - Overall Response Rate | IMBRUVICA®
Forest plot of the comparison of overall response rate (ORR).
Metastatic NSCLC Treatment Efficacy | LUMAKRAS™ (sotorasib)
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
Overall response rate | Download Table
RECIST Tumor Response Results | TURALIO® (pexidartinib)
RECIST Tumor Response Results | TURALIO® (pexidartinib)
Best Overall Response Rate (full analysis population) | Download Table
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Durable Response Rate
Tumor Response Rates | Advanced NSCLC | ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albuminbound)
MCL - Study 1104 Overall Response Rate | IMBRUVICA® (ibrutinib)
Durable Response Rate
Overall response rate (CR, CRi, PR, and HI) by baseline characteristics | Download Scientific Diagram
Efficacy | BALVERSA® (erdafitinib) HCP
![PDF] Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b69b299e42ca49585c4070db17f53396bee4a3b9/127-Table16-2-1.png "PDF] Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial | Semantic Scholar")
PDF] Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial | Semantic Scholar
